We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
SPIKEVAX COVID-19 VACCINE (Moderna Australia Pty Ltd)
Product name
SPIKEVAX COVID-19 VACCINE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
54 (255 working days)
Active ingredients
elasomeran
Registration type
EOI
Indication
SPIKEVAX COVID-19 VACCINE (suspension for injection) now also has provisional approval for the indication below:
Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 6 years of age and older.
The use of this vaccine should be in accordance with official recommendations.
The decision has been made on the basis of short-term efficacy and safety data. Continued approval depends on the evidence of longer term efficacy and safety from ongoing clinical trials and post-market assessment.
Registration process
Provisional registration
Involves early access to vital and life-saving medicines through time-limited registration